Figure 3.

Results from the Fine and Gray subdistribution hazard model stratified by sex.

∗Adjusted for age, sex, race, cause and vintage of CKD, baseline comorbidities including diabetes, CVD-related comorbidities, respiratory diseases and cancer, baseline usage of immunosuppressive medication, Renin-angiotensin-aldosterone system inhibitors (RAASi; angiotensin-converting-enzyme inhibitors and Angiotensin receptor blockers) and sodium-glucose cotransporter-2 (SGLT2) inhibitors. CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; KFRE, Kidney Failure Risk Equation.